Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 7/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.50 |
| ▸ | NOS2 | P35228 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | NOS1 | P29475 | 3/20 | 0.48 |
| ▸ | NOS3 | P29474 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | F12 | P00748 | 1/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7635931 | 0.80 | MASP2 (0.43) | IDO1NOS1PRSS1PRSS3F2 | |
| SCHEMBL1791607 | 0.80 | GRIN2B (0.59) | GRIN2BGRIN1NOS2SIGMAR1GRIN2D | |
| SCHEMBL7630047 | 0.78 | NOS1 (0.57) | GRIN2BGRIN1NOS2IDO1NOS1 | |
| SCHEMBL7260847 | 0.78 | GRIN2B (0.47) | GRIN2BGRIN1NOS2IDO1NOS1 | |
| SCHEMBL7260852 | 0.78 | GRIN2B (0.47) | GRIN2BGRIN1NOS2IDO1NOS1 | |
| SCHEMBL689470 | 0.77 | GRIN2B (0.50) | GRIN2BGRIN1NOS2SIGMAR1GRIN2D | |
| SCHEMBL2500288 | 0.71 | CES2 (0.48) | GRIN2BGRIN1NOS2 | |
| SCHEMBL45769 | 0.71 | GRIN2B (0.68) | GRIN2BGRIN1NOS2SIGMAR1GRIN2D | |
| SCHEMBL1795835 | 0.71 | GRIN2D (0.53) | GRIN2BGRIN1IDO1SIGMAR1GRIN2D | |
| Hydrochloric Acid SCHEMBL4629266 | 0.70 | GRIN2B (0.72) | GRIN2BGRIN1NOS2SIGMAR1GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019185586-A1 | LIGANDS FOR ENHANCED IMAGING AND DRUG DELIVERY TO NEUROBLASTOMA CELLS | UNIVERSIDAD COMPLUTENSE DE MADRID (ES) | 2019-10-03 | — | — | WO | disclosed |
| US-9493472-B2 | Substituted benzoxazoles | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-15 | — | — | US | disclosed |
| US-20160137647-A1 | SUBSTITUTED BENZOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-19 | — | — | US | disclosed |
| US-20160108027-A1 | SUBSTITUTED BENZOXAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-21 | — | — | US | disclosed |
| EP-1401502-A1 | PHARMACEUTICAL FORMULATION | AstraZeneca AB (SE) | 2004-03-31 | — | — | EP | disclosed |
| EP-1347955-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS | AstraZeneca AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| WO-2003000293-A1 | PHARMACEUTICAL FORMULATION | ASTRAZENECA AB (SE) | 2003-01-03 | — | — | WO | disclosed |
| EP-1237559-A1 | PHARMACEUTICAL COMBINATIONS | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| WO-2002044145-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS | ASTRAZENECA AB (SE) | 2002-06-06 | — | — | WO | disclosed |
| US-6399658-B1 | REDUCING DRUG SIDE EFFECT | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2002-06-04 | — | — | US | disclosed |
| WO-2001039781-A1 | PHARMACEUTICAL COMBINATIONS | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
| EP-1004304-A1 | COMPOSITION CONTAINING ASCORBIC ACID | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-05-31 | — | — | EP | disclosed |
| EP-0178121-B1 | IMPROVED FORMULATION OF ANTIINFLAMMATORY DRUGS | PFIZER INC. (US) | 1990-06-13 | — | — | EP | disclosed |
| US-4636498-A | OXICAMS, ANTIULCER, ANTISECRETORY 2-GUANIDINO-4-(4-IMIDAZOLYL) THIAZOLES | PFIZER INC. (US) | 1987-01-13 | — | — | US | disclosed |
| EP-0178121-A2 | Improved formulation of antiinflammatory drugs | PFIZER INC. (US) | 1986-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137647-A1 | SUBSTITUTED BENZOXAZOLES | TBXA2R, XDH, CYP4X1 | GRIN2B 3369/4885GRIN1 3224/4885NOS2 3916/4885 |
| US-20160108027-A1 | SUBSTITUTED BENZOXAZOLES | TBXA2R, XDH, CYP4X1 | GRIN2B 3369/4885GRIN1 3224/4885NOS2 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.